MedPath

GlaxoSmithKline

GlaxoSmithKline logo
🇬🇧United Kingdom
Ownership
Public
Established
1929-01-01
Employees
70.2K
Market Cap
$90B
Website
http://www.gsk.com
Introduction

GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Investigating the Efficacy of an Occluding Dentifrice in Providing Relief From Dentinal Hypersensitivity

Phase 3
Completed
Conditions
Dentin Sensitivity
Interventions
First Posted Date
2016-07-14
Last Posted Date
2017-05-25
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
242
Registration Number
NCT02832375
Locations
🇺🇸

GSK Investigational Site, Las Vegas, Nevada, United States

A Positron Emission Tomography (PET) Imaging Study to Investigate the Biodistribution and Clearance of an Albumin Binding Domain Antibody (AlbudAb) GSK3128349 in Healthy Male Subjects

Phase 1
Completed
Conditions
Drug-Related Side Effects and Adverse Reactions
Interventions
Drug: 89Zr-GSK3128349 1 mg
First Posted Date
2016-07-12
Last Posted Date
2018-09-07
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
8
Registration Number
NCT02829307
Locations
🇳🇱

GSK Investigational Site, Zuidlaren, Netherlands

Efficacy and Safety Study of GSK1278863 in Japanese Hemodialysis Subjects With Anemia Associated With Chronic Kidney Disease Who Are Not Taking Erythropoiesis Stimulating Agents

Phase 3
Completed
Conditions
Anaemia
Interventions
First Posted Date
2016-07-12
Last Posted Date
2019-12-03
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
28
Registration Number
NCT02829320
Locations
🇯🇵

GSK Investigational Site, Yamagata, Japan

Warming Sensation and Tolerability Study of Acetylcysteine 2% Oral Solution for Productive Cough

Phase 3
Completed
Conditions
Common Cold
Interventions
Drug: Acetylcystine
First Posted Date
2016-07-04
Last Posted Date
2017-01-31
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
58
Registration Number
NCT02822287
Locations
🇩🇪

GSK Investigational Site, Erfurt, Thueringen, Germany

Efficacy and Safety of GSK1358820 in Subjects With Overactive Bladder

Phase 3
Completed
Conditions
Urinary Bladder, Overactive
Interventions
Drug: Placebo
Drug: Antibiotic therapy
Other: King's Health Questionnaire (KHQ)
Other: Bladder diary
Other: Overactive Bladder Symptom Score (OABSS)
Other: Treatment Benefit Scale (TBS)
First Posted Date
2016-07-01
Last Posted Date
2020-11-27
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
250
Registration Number
NCT02820844
Locations
🇯🇵

GSK Investigational Site, Yamanashi, Japan

Immune Profile in Subjects With New Onset Type 1 Diabetes

Not Applicable
Completed
Conditions
Diabetes Mellitus, Type 1
Interventions
Procedure: Inguinal lymph node fine needle aspirate biopsy
Procedure: Inguinal lymph node core biopsy
Procedure: Peripheral blood collection
Other: Pre- and post-biopsy questionnaire
First Posted Date
2016-06-16
Last Posted Date
2019-02-27
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
22
Registration Number
NCT02801942
Locations
🇬🇧

GSK Investigational Site, Cardiff, United Kingdom

Dose-escalation Study of GSK2330672 in Japanese Healthy Male Volunteers

Phase 1
Completed
Conditions
Cholestasis
Interventions
Drug: GSK2230672
Drug: Placebo
First Posted Date
2016-06-16
Last Posted Date
2016-11-09
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
16
Registration Number
NCT02801981
Locations
🇯🇵

GSK Investigational Site, Tokyo, Japan

A Study Comparing the Effect of Albiglutide With Exenatide on Regional Brain Activity Related to Nausea in Healthy Subjects

First Posted Date
2016-06-16
Last Posted Date
2020-10-30
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
5
Registration Number
NCT02802514
Locations
🇺🇸

GSK Investigational Site, Boston, Massachusetts, United States

Efficacy and Safety Study of Tafenoquine (TQ) Co-administered With Dihydroartemisinin-piperaquine (DHA-PQP) for the Radical Cure of Plasmodium Vivax (P. Vivax) Malaria

Phase 3
Completed
Conditions
Malaria, Vivax
Interventions
Drug: Dihydroartemisinin-piperaquine (DHA-PQP)
Drug: ACT plus PQ (Rescue medication)
Drug: PQ (End of study treatment)
First Posted Date
2016-06-16
Last Posted Date
2020-07-24
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
150
Registration Number
NCT02802501
Locations
🇮🇩

GSK Investigational Site, Jakarta, Indonesia

An Efficacy Study of Umeclidinium/Vilanterol With Tiotropium/Olodaterol in COPD Patients

Phase 4
Completed
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Drug: TIO/OLO
Drug: Albuterol/salbutamol
First Posted Date
2016-06-15
Last Posted Date
2018-07-02
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
236
Registration Number
NCT02799784
Locations
🇬🇧

GSK Investigational Site, Swinton, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath